Modality Solutions has been actively involved in NIH clinical trials for an Ebola vaccine since 2015. Our key partner in the Democratic Republic of Congo is Dr. Jean-Jacques Muyembe. He was interviewed in the DRC by Monica Villamizar of the PBS News Hour on January 16, 2020.
Click here to read the transcript of the interview.
In addition, Dr. Muyembe was named to Nature’s 10. This year’s Nature, Vol. 576, annual list was made up of ten people who mattered in science for 2019. His Nature’s 10 feature was titled “Jean-Jacque Muyembe Tamfum – Ebola fighter. The co-discoverer of Ebola faces his tenth battle with the virus in the DRC – his toughest yet.” The article covers his initial investigation of an unidentified ailment (later named Ebola) in 1976 deep in the jungles of what now is the DRC to how a 680-person, controlled clinical trial in 2019 led by his team, and supported by Modality Solutions, showed a 90% survival rate for those treated with antibody-based drugs shortly after infection.
Today, four leading life science companies—Suttons Creek, Modality Solutions, CLINTREX, and ToxStrategies—announce their unification...
read Details
Modality Solutions is proud to announce the launch of our new Greenwood Lab—a state-of-the-art...
read Details
Congratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for...
read Details
